Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology

被引:14
作者
Neely, Michael [1 ]
Bayard, David [1 ]
Desai, Amit [2 ]
Kovanda, Laura [2 ]
Edginton, Andrea [3 ]
机构
[1] Univ Southern Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA
[2] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[3] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
关键词
clinical pharmacology; modeling; pediatric; pharmacometrics; simulation; therapeutic drug monitoring; BODY-SURFACE-AREA; POPULATION PHARMACOKINETICS; DRUG DEVELOPMENT; SCAVENGED SAMPLES; CHILDREN; EXPOSURE; PRETERM; SIZE; VALGANCICLOVIR; FLUCONAZOLE;
D O I
10.1002/jcph.1316
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pediatric clinical pharmacology now encompasses a wide range of activities, including drug pharmacokinetic and pharmacodynamic modeling and simulation, also known as pharmacometrics. Pediatric clinical pharmacologists may be physicians but are more likely to be pharmacists or PhD scientists, and pediatric clinical pharmacology today is largely a research specialty rather than a subspecialty for direct patient care. Pharmacometrics, including "top-down" population modeling and "bottom-up" physiologically based pharmacokinetic modeling, has become an indispensable tool for pharmaceutical industry scientists, government regulators, academic researchers, and even a handful of patient-oriented practitioners. This review summarizes the application of pharmacometrics within each of these domains and predicts future trends of further applications across the spectrum of pediatric clinical pharmacology from drug development to patient care.
引用
收藏
页码:S73 / S85
页数:13
相关论文
共 63 条
[1]   Optimal Design of Pharmacokinetic Studies [J].
Aarons, Leon ;
Ogungbenro, Kayode .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (03) :250-255
[2]   Mechanism-based concepts of size and maturity in pharmacokinetics [J].
Anderson, B. J. ;
Holford, N. H. G. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :303-332
[3]   Pharmacometrics: A multidisciplinary field to facilitate critical thinking in drug development and translational research settings [J].
Barrett, Jeffrey S. ;
Fossler, Michael J. ;
Cadieu, K. David ;
Gastonguay, Marc R. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (05) :632-649
[4]  
Bayard DS, 2017, J PHARMACOKINET PHAR, V44, P95, DOI 10.1007/s10928-016-9498-5
[5]   A Bayesian approach to tracking patients having changing pharmacokinetic parameters [J].
Bayard, DS ;
Jelliffe, RW .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2004, 31 (01) :75-107
[6]   PHARMACOMETRICS - A NEW JOURNAL SECTION [J].
BENET, LZ ;
ROWLAND, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (04) :349-350
[7]  
Benjamin DK, 2018, PEDIATR INFECT DIS J, V37, P992, DOI [10.1097/INF.0000000000001996, 10.1097/inf.0000000000001996]
[8]   Population pharmacokinetics of cefepirne in the neonate [J].
Capparelli, E ;
Hochwald, C ;
Rasmussen, M ;
Parham, A ;
Bradley, J ;
Moya, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) :2760-2766
[9]   Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia [J].
Cies, Jeffrey J. ;
Fugarolas, Keri N. ;
Moore, Wayne S., II ;
Mason, Robert W. ;
Menkiti, Ogechukwu R. .
PHARMACOTHERAPY, 2017, 37 (04) :456-463
[10]   Population Pharmacokinetics of Piperacillin Using Scavenged Samples From Preterm Infants [J].
Cohen-Wolkowiez, Michael ;
Benjamin, Daniel K., Jr. ;
Ross, Ashley ;
James, Laura P. ;
Sullivan, Janice E. ;
Walsh, Michele C. ;
Zadell, Arlene ;
Newman, Nancy ;
White, Nicole R. ;
Kashuba, Angela D. M. ;
Ouellet, Daniele .
THERAPEUTIC DRUG MONITORING, 2012, 34 (03) :312-319